TLIS Stock Overview
Talis Biomedical Corporation operates as a molecular diagnostic company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Talis Biomedical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.01 |
| 52 Week High | US$9.32 |
| 52 Week Low | US$4.35 |
| Beta | 1.74 |
| 1 Month Change | 1.24% |
| 3 Month Change | 11.65% |
| 1 Year Change | 21.84% |
| 3 Year Change | -95.02% |
| 5 Year Change | n/a |
| Change since IPO | -97.84% |
Recent News & Updates
Recent updates
We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate
Aug 16
Talis Biomedical reports Q2 results
Aug 02Talis Biomedical Aims For Manufacturing Turnaround
Mar 17Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely
Feb 08Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Nov 04Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Jul 21News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat
May 18Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 14Shareholder Returns
| TLIS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.6% | 1.4% | 1.2% |
| 1Y | 21.8% | -0.7% | 24.7% |
Return vs Industry: TLIS exceeded the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: TLIS underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| TLIS volatility | |
|---|---|
| TLIS Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TLIS has not had significant price volatility in the past 3 months.
Volatility Over Time: TLIS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 99 | Rob Kelley | talisbio.com |
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women’s health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headquartered in Redwood, California.
Talis Biomedical Corporation Fundamentals Summary
| TLIS fundamental statistics | |
|---|---|
| Market cap | US$16.42m |
| Earnings (TTM) | -US$62.01m |
| Revenue (TTM) | US$2.13m |
7.7x
P/S Ratio-0.3x
P/E RatioIs TLIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLIS income statement (TTM) | |
|---|---|
| Revenue | US$2.13m |
| Cost of Revenue | US$40.74m |
| Gross Profit | -US$38.60m |
| Other Expenses | US$23.41m |
| Earnings | -US$62.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -34.03 |
| Gross Margin | -1,808.86% |
| Net Profit Margin | -2,905.67% |
| Debt/Equity Ratio | 0% |
How did TLIS perform over the long term?
See historical performance and comparison